HEXPOL AB Operating Income Over Time
| 4QT1 Stock | EUR 7.16 0.06 0.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out HEXPOL AB Performance and HEXPOL AB Correlation. HEXPOL |
Cross Equities Operating Income Analysis
Compare HEXPOL AB and related stocks such as Abbott Laboratories, DANAHER (DAPSG), and Merck Operating Income Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABL | 3.2 B | 3.2 B | 3.2 B | 3.2 B | 3.2 B | 3.2 B | 3.2 B | 1.7 B | 3.6 B | 4.5 B | 5.4 B | 8.4 B | 8.4 B | 6.5 B | 6.8 B | 7.8 B | 5.9 B |
| DAP | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 3 B | 3.4 B | 3.3 B | 4.2 B | 6.4 B | 7.5 B | 5.2 B | 4.9 B | 5.6 B | 5 B |
| 6MK | 6 B | 6 B | 6 B | 6 B | 6 B | 6 B | 6 B | 7.3 B | 8.9 B | 12.2 B | 5.5 B | 13.2 B | 18.3 B | 3 B | 20.2 B | 23.3 B | 24.4 B |
| AMD | (382 M) | (382 M) | (382 M) | (382 M) | (382 M) | (382 M) | (382 M) | 204 M | 451 M | 631 M | 1.4 B | 3.6 B | 1.3 B | 401 M | 2.1 B | 3.7 B | 3.9 B |
| 4I1 | 10.8 B | 10.8 B | 10.8 B | 10.8 B | 10.8 B | 10.8 B | 10.8 B | 11.5 B | 11.3 B | 10.4 B | 11.6 B | 13 B | 12.2 B | 12.2 B | 13.4 B | 14.9 B | 13.4 B |
| W8V | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 220 B | 198 B | 176 B |
| TOTB | 4.6 B | 4.6 B | 4.6 B | 4.6 B | 4.6 B | 4.6 B | 4.6 B | 7 B | 15.3 B | 15.4 B | (7.3 B) | 23.9 B | 49.7 B | 30.9 B | 24.1 B | 27.7 B | 20 B |
| AMG | 9.8 B | 9.8 B | 9.8 B | 9.8 B | 9.8 B | 9.8 B | 9.8 B | 10 B | 10.3 B | 9.7 B | 9.1 B | 7.6 B | 9.6 B | 7.9 B | 7.3 B | 9.1 B | 7.2 B |
| HBC1 | 21.1 B | 21.1 B | 21.1 B | 21.1 B | 17 B | 17.2 B | 8.8 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 13.9 B | 12.7 B |
| HK2C | 6.3 B | 6.3 B | 6.3 B | 6.3 B | 6.3 B | 6.3 B | 6.3 B | 7.2 B | 9.5 B | 8.5 B | 11.2 B | 13.6 B | 10.4 B | 8.5 B | 10 B | 11.6 B | 10.4 B |
HEXPOL AB and related stocks such as Abbott Laboratories, DANAHER (DAPSG), and Merck Operating Income description
Operating Income is the amount of profit realized from HEXPOL AB operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of HEXPOL AB is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| HEXPOL AB | 4QT1 |
Specialization | Basic Materials, Specialty Chemicals |
| Business Address | Skeppsbron 3, Malm, |
| Exchange | Frankfurt Exchange |
EUR 7.16
Other Information on Investing in HEXPOL Stock
HEXPOL AB financial ratios help investors to determine whether HEXPOL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEXPOL with respect to the benefits of owning HEXPOL AB security.